
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.66377
Dentistry
Infectious Disease
Therapeutics
Antibacterial Activity of Cissus quadrangularis (Veldt Grape) Against Porphyromonas gingivalis, a Keystone Pathogen in Periodontal Disease: An In Vitro Study
Muacevic Alexander
Adler John R
Nair Aathira R 1
Blaisie Rajula Prem 1
PL Ravishankar 1
Geddam Sai Sri Soury 1
B Subhashini 1
S Lochini 1
1 Periodontology, SRM Kattankulathur Dental College and Hospital, Chennai, IND
Prem Blaisie Rajula premblam@srmist.edu.in
7 8 2024
8 2024
16 8 e6637727 6 2024
7 8 2024
Copyright © 2024, Nair et al.
2024
Nair et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/272096-antibacterial-activity-of-cissus-quadrangularis-veldt-grape-against-porphyromonas-gingivalis-a-keystone-pathogen-in-periodontal-disease-an-in-vitro-study
Background: Porphyromonas gingivalis, a keystone pathogen and one of the primary pathogens responsible for periodontitis, leads to a chronic inflammatory condition that destroys the periodontal tissues and ultimately results in tooth loss. While conventional non-surgical therapy combined with antibiotics and local drug delivery systems are commonly used to treat periodontitis, certain medicinal herbs have also demonstrated efficacy in its prevention. Cissus quadrangularis L. (CQ), a perennial plant from the Vitaceae family, is widely recognized and used as a medicinal herb in many tropical countries, predominantly in India, Sri Lanka, Thailand, Java, West Africa, and the Philippines.

Aim: The aim of the study was to determine the antibacterial activity of CQ against the periodontal keystone pathogen P. gingivalis.

Method: Aqueous and ethanolic extracts of CQ were prepared using a Soxhlet extractor. The antibacterial effectiveness of these extracts against the periodontal pathogen P. gingivalis was evaluated at different concentrations, and the minimal inhibitory concentration (MIC) was determined using broth microdilution.

Results: The ethanolic extract of CQ mixed with 10% dimethyl sulfoxide (DMSO) showed higher inhibition compared to the aqueous extract of CQ against P. gingivalis.

Conclusion: Our study revealed the potent inhibitory effects of CQ against P. gingivalis. Both aqueous and ethanolic extracts displayed MIC values of 500 µg/mL. Notably, the ethanolic extract of CQ, dissolved in 10% DMSO, demonstrated superior efficacy with a lower IC50 value of 194.36 µg/mL. These findings indicate promising potential for CQ in the management of periodontal disease.

porphyromonas gingivalis
minimum inhibitory concentration
ethanolic extract
cissus quadrangularis
antibacterial activity
==== Body
pmcIntroduction

The keystone pathogen Porphyromonas gingivalis is prominently implicated in periodontitis, a chronic inflammatory condition that results in tooth loss and the damage of gingiva, alveolar bone, and periodontal ligaments [1]. Among the myriad bacterial species inhabiting the oral cavity, this specific gram-negative rod bacterium is non-motile and requires anaerobic conditions to survive. After 3-5 days of incubation, it forms black-pigmented colonies on supplemented blood agar plates [2,3]. By interacting with commensal Streptococci, P. gingivalis causes secondary infections in periodontal tissues [4]. Its capacity to elude host immune responses and disseminate via cell-to-cell interactions or hematogenous routes sustains persistent irritation in the peripheral regions [5].

Presently, periodontitis management involves systemic and localized antibiotic therapy, sometimes coupled with surgical interventions for addressing deep-pocket irritations [6]. Anaerobic bacteria, especially P. gingivalis, are the target of antibiotics. A range of antibiotics such as metronidazole, amoxicillin, amoxicillin/clavulanic acid, clindamycin, tetracycline, and fluoroquinolones are utilized alongside mechanical debridement [7,8].

Failure to perform debridement can lead to antibiotics being unable to penetrate biofilm, resulting in significantly higher minimal inhibitory concentrations (MIC) [9]. Moreover, P. gingivalis strains exhibit considerable resistance rates, reaching up to 21.56% for metronidazole, 25.49% for amoxicillin, and 23.52% for clindamycin [10]. Notable resistance is also observed for penicillin, erythromycin, azithromycin, and tetracycline [11].

As antibiotic resistance escalates, the imperative for new antimicrobials intensifies, yet the rate of new antibiotic discoveries has declined [12]. Medicinal plants offer another avenue for combating P. gingivalis infections. Not only do plant species represent a diverse reservoir of antibacterial compounds [13], but ethnobotanical knowledge can guide the selection of plant extracts for discovering novel antibacterials [14]. Extensive ethnobotanical documentation exists regarding plant usage for oral health, yet further research is assured to establish the pharmacological efficacy of these ethnomedicinal practices against dental pathogens.

Cissus quadrangularis (CQ), also known as Veldt Grape or Devil's Backbone, belongs to the Vitaceae family. It is recognized by various names, including Asthisamharaka, Hadjod, Pirandai, Mangara Valli, and Vitis quadrangularis [15-19]. Utilized in Ayurvedic and Siddha medicine traditions, it offers a range of therapeutic benefits, including antimicrobial, antiulcer, antioxidative, anti-osteoporotic, gastroprotective, cholinergic, antihyperglycemic, and cardiovascular properties [19]. This cactus-like plant is characterized by jointed climbers with simple tendrils and leaves that are either simple or lobed, cordate, serrate, or dentate. Its small, greenish-white, bisexual, and tetramerous flowers complement its versatile medicinal properties (Figure 1). This plant possesses the capability to mend bones, earning it the epithet "bone setter" [20].

It was discovered to exhibit anti-osteoporotic, antioxidant, antimicrobial, anticonvulsant, sedative, neuropharmacological, central nervous system (CNS) activity, anthelmintic, antidiabetic, antistress, anticancerous potential, and antinociceptive properties [18,21].

Previous research has revealed varying degrees of antibacterial efficacy against different microorganisms [16], yet scant literature has examined its antibacterial activity specifically against P. gingivalis. Therefore, this study aimed to assess the antibacterial potential of CQ against this significant periodontal pathogen.

Materials and methods

Collection of sample

Commercially available CQ powder (Bixa Botanicals, Dhar, India), also known as Hadjod stem powder, was used.

Preparation of ethanolic extract of CQ (Soxhlet extraction method)

Ethanolic extract of CQ was prepared using a Soxhlet extractor (Figure 1). Among conventional methods, Soxhlet was the most powerful method and had the most extraction yields [22]. The solvent (250 mL ethanol) was filled in the percolator. Finely ground powder of CQ (25 g) was packed using Whatman filter paper and placed inside the thimble. The solvent (ethanol) was heated by adjusting the temperature of the mantle to 50°C to reflux. The solvent vapor that travels up the distillation arm was cooled by the water that circulates in the condenser. The active compounds of CQ were extracted in ethanol. The cycle was repeated thrice to enable the complete extraction of the bioactive compounds present in CQ. After extraction, the solvent was evaporated to yield the extracted compounds (Figure 2). The ethanolic extract of CQwas dissolved in 10% dimethyl sulfoxide (DMSO) at a concentration of 25 mg/mL. Similarly, the aqueous extract was also obtained using the Soxhlet extraction method.

Figure 1 Extract preparation using a Soxhlet apparatus

Figure 2 Aqueous and ethanolic extract of Cissus quadrangularis

Preparation of bacterial suspension

From the maintained frozen stock cultures of P. gingivalis (ATCC No-33277), a small quantity of cells was recovered and subcultured. Brain heart infusion (BHI) broth was used as the culture medium to support the growth of bacteria. This culture was transferred into tubes containing 2 mL of the BHI medium to obtain a culture suspension of P. gingivalis. The selected test bacterial strain was adjusted to 0.5 McFarland turbidity standards.

MIC by broth dilution method

The MIC was calculated using the broth microdilution method with a 96-well polystyrene flat bottom plate. From columns 2 to 8, 50 μL of Mueller Hinton broth (MHB) was added to the microtiter plate. Then, 100 μL of the sample was added to the first well and serially diluted to the eighth well (1000 μg/mL to 7.8 μg/mL) (rows A and D: aqueous extract of CQ; rows B and E: ethanolic extract of CQdissolved in 10% DMSO). The 10th and 11th wells served as sterility and negative controls. Then, 50 μL of the P. gingivalis (ATCC® 33277) suspensions (0.5 McFarland) was added to all columns except the sterility column (Figure 3). The 96-well plate was read at 600 nm after being incubated for 24 hours at 37 °C. MIC was determined by comparing the growth rate of the tested bacterial strain with the negative controls. The lowest extract concentration that inhibited bacterial growth was noted as MIC.

Figure 3 Microdilution. Rows A and D: aqueous extract of CQ. Rows B and E: ethanolic extract of CQ dissolved in 10% DMSO.

CQ: Cissus quadrangularis L., DMSO: dimethyl sulfoxide.

Results

The MIC data reveal intriguing insights into the inhibitory potential of Sample 1 (an aqueous extract of CQ) and Sample 2 (an ethanolic extract of CQ dissolved in 10% DMSO) at varying concentrations. The concentrations tested ranged from 1000 µg/mL to 7.8125 µg/mL. The MIC, representing the minimum concentration at which microbiological development is prevented, is a critical parameter in assessing the effectiveness of antimicrobial agents. The MIC of Samples 1 and 2 was determined to be 500 µg/mL, with inhibitory percentages of 70.19% and 77.57%, respectively (Table 1 and Figure 5). As per standard protocol, the IC50 of Samples 1 and 2 was determined to be 240.46 µg/mL and 194.36 µg/mL, respectively. The inhibitory effect of the ethanolic extract of CQ dissolved in 10% DMSO was better than that of the aqueous extract of CQ. The broth microdilution method illustrated in Figure 3 provides a visual representation of the antimicrobial activity of the samples, highlighting their ability to inhibit bacterial growth at varying concentrations. Furthermore, Figure 4 depicts the activity of the samples compared to the control in terms of optical density (600 nm), reaffirming their effectiveness in suppressing bacterial proliferation.

Table 1 Inhibitory Percentage and IC50

Concentration (µg/mL)	Sample 1	Sample 1 - IC50	Sample 2	Sample 2 - IC50	
1000	83.56	240.46 µg/mL	87.33	194.36 µg/mL	
500	70.19	77.57	
250	53.37	59.75	
125	39.09	41.47	
62.5	26.34	29.26	
31.25	23.89	25.34	
15.63	20.74	24.04	
7.81	7.07	18.89	

Figure 4 Minimum inhibitory concentration of aqueous and ethanolic extract of Cissus quadrangularis

Sample 1: Aqueous extract of Cissus quadrangularis.

Sample 2: Ethanolic extract of Cissus quadrangularis dissolved in 10% DMSO.

MIC: minimum inhibitory concentration, DMSO: dimethyl sulfoxide, OD: optical density.

Figure 5 Percentage inhibition of aqueous and ethanolic extract of Cissus quadrangularis

Sample 1: Aqueous extract of Cissus quadrangularis.

Sample 2: Ethanolic extract of Cissus quadrangularis dissolved in 10% DMSO.

DMSO: dimethyl sulfoxide.

Discussion

Gingivitis and periodontitis are prevalent periodontal disorders that impact a substantial proportion of the worldwide population. These chronic inflammatory diseases are predominantly caused by an excess of certain anaerobic bacterial species in dental plaque. This is usually treated with mechanical methods (scaling and root planing, or SRP), but these methods are not always successful because of pathogens that can invade tissue. Systemic and local antibiotics may be beneficial when used in conjunction with mechanical treatment. However, widespread antibiotic use can lead to antibiotic resistance. As a result, research over the past ten years has concentrated on medicinal plants with anti-inflammatory and antibacterial properties to treat these ailments.

The foundations of traditional medicinal systems have historically been plants [23]. Plant extracts, in particular, have emerged as promising natural antibacterial agents with diverse therapeutic applications for combating pathogenic bacteria. CQ, for instance, contains a plethora of beneficial compounds such as carotene, phytosterol, terpenoids, β-sitosterol, δ-amyrin, δ-amyrone, calcium, flavonoids like quercetin, vitamin C, and stilbene derivatives such as resveratrol, piceatannol, pallidol, perthenocissin, and phytosterols [15].

The aqueous and ethanolic extracts of CQ were selected for the current investigation in order to assess their antibacterial activity against P. gingivalis, the keystone periodontal pathogen. The results of our study shed light on the inhibitory potential of two different samples of CQ aqueous and ethanolic extracts against P. gingivalis, a prominent periodontal pathogen. The MIC data reveal the inhibitory potential of Sample 1 (an aqueous extract of CQ) and Sample 2 (an ethanolic extract of CQ dissolved in 10% DMSO) at varying concentrations. The concentrations tested ranged from 1000 µg/mL to 7.8125 µg/mL. The MIC of Samples 1 and 2 was determined to be 500 µg/mL. Additionally, the inhibitory percentages of Sample 1 and Sample 2 were found to be 70.19% and 77.57%, respectively.

The determination of the half-maximal inhibitory concentration (IC50) further elucidated the potency of the samples, with Sample 2 exhibiting a lower IC50 value (194.36 µg/mL) compared to Sample 1 (240.46 µg/mL). These findings indicate that the ethanolic extract of CQ formulated with 10% DMSO possessed enhanced antibacterial activity against P. gingivalis compared to the aqueous extract (Sample 1). The results were consistent with the findings of Nadhini et al., who reported that the ethanolic extract of CQ exhibited the highest level of antibacterial activity against clinical pathogens [24]. They stated that the ethanolic extract was most frequently used and showed a reasonable antibacterial effect.

Multiple clinical investigations have indicated that administering CQ within a range of 1.2-10 g/day for durations spanning 4-12 weeks led to an acceleration in bone fracture healing, without encountering severe adverse events (AEs). These clinical observations find reinforcement in various in vivo and in vitro studies focusing on bone-related outcomes. Such collective evidence underscores the potential of CQ as an alternative approach to mitigating bone loss [25,26].

The traditional medicinal practice of Ayurveda has long utilized CQ to address a spectrum of diseases and ailments [27]. Its recognized osteogenic properties prompted an exploration into its potential application for periodontitis. Our findings confirm the antibacterial properties of CQ, shedding light on its potential therapeutic role in combating periodontal infections. The efficacy of both samples in preventing the growth of P. gingivalis is of significant clinical relevance, as it suggests their potential utility in the prevention, treatment, and management of periodontal diseases.

The strength of our study lies in its novel focus on the antibacterial activity of CQ against P. gingivalis, a key pathogen in periodontal disease. The demonstrated efficacy of CQ, particularly the ethanolic extract, suggests its potential as an adjunctive therapy for periodontal diseases. Furthermore, incorporating CQ into local drug delivery systems, such as mouth rinses and gels, could enhance its therapeutic application in dental practice.

Despite the promising results, the study is subject to certain limitations. While the extracts effectively targeted P. gingivalis, their efficacy against other periodontal pathogens remains unknown due to the exclusive focus on this single bacterium. Furthermore, the controlled laboratory environment (in vitro) necessitates clinical trials to validate their effectiveness for further clinical applications.

Conclusions

In conclusion, our findings highlight the significant antibacterial properties of CQ aqueous and ethanolic extracts against Porphyromonas gingivalis. The demonstrated efficacy of CQ extracts in inhibiting P. gingivalis opens new avenues for the development of innovative periodontal treatment strategies. To fully harness the potential of CQ extracts, further research is necessary to delve into the underlying mechanisms of their antibacterial action. Understanding these mechanisms will provide valuable insights into how these extracts can effectively combat P. gingivalis .

The authors are very grateful to Dr. Kesavaram Padmavathy, Professor, Department of Microbiology, Sree Balaji Dental College and Hospital, Chennai, India, and Prashanth KK, Director, SimBioen Labs and Scientific Private Limited, Chennai, India, for providing the necessary facilities to carry out this study. They would also like to acknowledge the use of ChatGPT (Open AI, Open AI Inc, San Francisco, California, USA) in improving the grammar, punctuation, and overall clarity of the scientific paper.

Disclosures

Author Contributions

Human subjects: All authors have confirmed that this study did not involve human participants or tissue.

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Prem Blaisie Rajula, Aathira R. Nair, Ravishankar PL, Sai Sri Soury Geddam, Subhashini B, Lochini S

Acquisition, analysis, or interpretation of data:  Prem Blaisie Rajula, Aathira R. Nair, Ravishankar PL, Sai Sri Soury Geddam, Subhashini B, Lochini S

Drafting of the manuscript:  Prem Blaisie Rajula, Aathira R. Nair, Ravishankar PL, Sai Sri Soury Geddam, Subhashini B, Lochini S

Critical review of the manuscript for important intellectual content:  Prem Blaisie Rajula, Aathira R. Nair, Ravishankar PL, Sai Sri Soury Geddam, Subhashini B, Lochini S

Supervision:  Prem Blaisie Rajula, Ravishankar PL
==== Refs
References

1 Porphyromonas gingivalis periodontal infection and its putative links with Alzheimer's disease Mediators Inflamm Singhrao SK Harding A Poole S Kesavalu L Crean S 137357 2015 2015 26063967
2 Porphyromonas gingivalis: major periodontopathic pathogen overview J Immunol Res Mysak J Podzimek S Sommerova P 476068 2014 2014 24741603
3 The antimicrobial susceptibility of Porphyromonas gingivalis: genetic repertoire, global phenotype, and review of the literature Antibiotics (Basel) Conrads G Klomp T Deng D Wenzler JS Braun A Abdelbary MM 10 2021
4 Dual lifestyle of Porphyromonas gingivalis in biofilm and gingival cells Microb Pathog Sakanaka A Takeuchi H Kuboniwa M Amano A 42 47 94 2016 26456558
5 The atherogenic bacterium Porphyromonas gingivalis evades circulating phagocytes by adhering to erythrocytes Infect Immun Belstrøm D Holmstrup P Damgaard C Borch TS Skjødt MO Bendtzen K Nielsen CH 1559 1565 79 2011 21245264
6 Antibiotics/antimicrobials: systemic and local administration in the therapy of mild to moderately advanced periodontitis Periodontol 2000 Jepsen K Jepsen S 82 112 71 2016 27045432
7 Antibiotic resistance of subgingival species in chronic periodontitis patients J Periodontal Res Ardila CM Granada MI Guzmán IC 557 563 45 2010 20546113
8 Specific antibiotics in the treatment of periodontitis--a proposed strategy J Periodontol Beikler T Prior K Ehmke B Flemmig TF 169 175 75 2004 15025229
9 Susceptibility of Porphyromonas gingivalis in biofilms to amoxicillin, doxycycline and metronidazole Oral Microbiol Immunol Larsen T 267 271 17 2002 12354206
10 High resistance against clindamycin, metronidazole and amoxicillin in Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans isolates of periodontal disease Med Oral Patol Oral Cir Bucal Ardila CM López MA Guzmán IC 947 951 1 2010
11 Antimicrobial resistance in the subgingival microflora in patients with adult periodontitis. A comparison between The Netherlands and Spain J Clin Periodontol van Winkelhoff AJ Herrera Gonzales D Winkel EG Dellemijn-Kippuw N Vandenbroucke-Grauls CM Sanz M 79 86 27 2000 10703651
12 Antibacterial drug discovery in the resistance era Nature Brown ED Wright GD 336 343 529 2016 26791724
13 Plant natural products targeting bacterial virulence factors Chem Rev Silva LN Zimmer KR Macedo AJ Trentin DS 9162 9236 116 2016 27437994
14 Ethnobotanical approach versus random approach in the search for new bioactive compounds: support of a hypothesis Pharm Biol Gyllenhaal C Kadushin MR Southavong B 30 41 50 2012 22196581
15 Antibacterial activity of Cissus quadrangularis stem extract on the pathogenic and industrial waste watered bacteria Eur J Med Health Sci Mosaib MG Maruf MAA Islam R 28 38 2 2020
16 Antibacterial activity of Cissus quadrangularis Linn Indian J Pharm Sci Kashikar ND George I 245 247 68 2006 https://www.ijpsonline.com/abstract/antibacterial-activity-of-cissus-quadrangularis-linn-281.html
17 Antioxidant and antimicrobial activity of Cissus quadrangularis L J Med Food Chidambara Murthy KN Vanitha A Mahadeva Swamy M Ravishankar GA 99 105 6 2003 https://pubmed.ncbi.nlm.nih.gov/12935320/ 12935320
18 Bioactive compound analysis and bioactivities of endophytic bacteria from Cissus quadrangularis Int J Pharm Sci Res Anwar PZ Sezhian UG Narasingam A 5553 5560 11 2020 https://ijpsr.com/bft-article/bioactive-compound-analysis-and-bioactivities-of-endophytic-bacteria-from-cissus-quadrangularis/?view=fulltext
19 Analyzing the antihyperglycemic effect of Cissus quadrangularis and Bacopa monnieri on 3T3-L1 cell lines Cureus Katheeja R Manish S Ilangovar IGK Selvaraj J Vasugi S 0 16 2024 https://www.cureus.com/articles/217180-analyzing-the-antihyperglycemic-effect-of-cissus-quadrangularis-and-bacopa-monnieri-on-3t3-l1-cell-lines#!/
20 A preliminary study on in vitro antioxidant and in vivo anti-inflammatory activity of Cissus quadrangularis Linn Res J Pharm Technol Tiwari M Gupta PS Sharma N 2619 2624 14 2021 https://rjptonline.org/AbstractView.aspx?PID=2021-14-5-45
21 Evaluation of antidepressant activity of ethanolic extract of Cissus quadrangularis on swiss albino mice Res J Pharm Technol Kapadia S Kanase V 4197 4202 14 2021 https://rjptonline.org/AbstractView.aspx?PID=2021-14-8-33
22 Optimization of extraction conditions of bioactive compounds from Kurdistan species Urtica dioica Cureus Haido MH Matti AH Taher SM 0 16 2024 https://www.cureus.com/articles/240914-optimization-of-extraction-conditions-of-bioactive-compounds-from-kurdistan-species-urtica-dioica#!/
23 Osteogenic potential of cissus qudrangularis assessed with osteopontin expression Natl J Maxillofac Surg Singh N Singh V Singh RK Pant AB Pal US Malkunje LR Mehta G 52 56 4 2013 https://journals.lww.com/njms/fulltext/2013/04010/osteogenic_potential_of_cissus_qudrangularis.10.aspx 24163553
24 Screening of antibacterial activity of Cissus quadrangularis and Boerhavia diffusa against clinical pathogens Int J Sci Res Nandhini K Tharani J Sangeetha D 668 672 11 2022 https://www.ijsr.net/getabstract.php
25 Clinical evaluation of Cissus quadrangularis as osteogenic agent in maxillofacial fracture: A pilot study Ayu Brahmkshatriya HR Shah KA Ananthkumar GB Brahmkshatriya MH 169 173 36 2015 https://journals.lww.com/aayu/fulltext/2015/36020/clinical_evaluation_of_cissus_quadrangularis_as.11.aspx 27011718
26 The effect of Cissus quadrangularis L. on delaying bone loss in postmenopausal women with osteopenia: a randomized placebo-controlled trial Phytomedicine Benjawan S Nimitphong H Tragulpiankit P Musigavong O Prathanturarug S Pathomwichaiwat T 154115 101 2022 https://doi.org/10.1016/j.phymed.2022.154115 35523116
27 Guidelines for laboratory monitoring of treatment of persistent virus infections J Clin Virol Pillay D Emery VC Mutimer D 73 92 25 2002 https://pubmed.ncbi.nlm.nih.gov/12126724/ 12126724
